PASG

4.65

2.11% -0.10

Handel nachbörslich: 4.64 -0.01 -0.22%

Passage Bio Inc (PASG)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$4.75

Offen:

$4.63

24-Stunden-Volumen:

3,756

Relative Volume:

0.06

Marktkapitalisierung:

$14.96M

Einnahmen:

Nettoeinkommen (Verlust:

$-37.68M

KGV:

-0.3929

EPS:

-11.8364

Netto-Cashflow:

$-30.65M

1W Leistung:

+2.88%

1M Leistung:

+0.43%

6M Leistung:

-44.91%

1J Leistung:

-33.57%

1-Tages-Spanne:

$4.63

$4.8745

1-Wochen-Bereich:

$4.40

$4.8745

52-Wochen-Spanne:

$3.29

$20.00

Passage Bio Inc Stock (PASG) Company Profile

Firmenname

Passage Bio Inc

Sektor

Healthcare (1074)

Branche

Biotechnology (600)

Telefon

(267) 866-0312

Adresse

ONE COMMERCE SQUARE, PHILADELPHIA, PA

Mitarbeiter

Twitter

@passage_bio

Nächster Verdiensttermin

2026-08-11

Neueste SEC-Einreichungen

PASG's Discussions on Twitter

Compare PASG vs VRTX, REGN, ARGX, MRNA, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
PASG Passage Bio Inc	4.65	14.42M	0	-37.68M	-30.65M	-11.84
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Passage Bio Inc Stock (PASG) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-04-21	Herabstufung	Chardan Capital Markets	Buy → Neutral
2026-04-21	Herabstufung	TD Cowen	Buy → Hold
2026-04-21	Herabstufung	Wedbush	Outperform → Neutral
2026-03-31	Eingeleitet	Oppenheimer	Outperform
2026-02-10	Fortgesetzt	Chardan Capital Markets	Buy
2024-11-29	Fortgesetzt	Wedbush	Outperform
2024-09-03	Eingeleitet	Rodman & Renshaw	Buy
2022-03-08	Herabstufung	JP Morgan	Overweight → Neutral
2022-01-19	Herabstufung	Goldman	Buy → Neutral
2021-07-01	Eingeleitet	Raymond James	Outperform
2021-06-15	Eingeleitet	BTIG Research	Buy
2021-03-04	Hochstufung	Goldman	Neutral → Buy
2021-02-04	Eingeleitet	Guggenheim	Buy
2021-01-25	Eingeleitet	Wedbush	Outperform
2021-01-04	Hochstufung	JP Morgan	Neutral → Overweight
2020-12-11	Eingeleitet	Citigroup	Neutral
2020-08-14	Herabstufung	JP Morgan	Overweight → Neutral
2020-06-25	Herabstufung	Goldman	Buy → Neutral
2020-03-25	Eingeleitet	Chardan Capital Markets	Buy
2020-03-24	Eingeleitet	Cowen	Outperform
2020-03-24	Eingeleitet	Goldman	Buy
2020-03-24	Eingeleitet	JP Morgan	Overweight

Alle ansehen

Passage Bio Inc Aktie (PASG) Neueste Nachrichten

Sep 05, 2026

SPRY, PASG, BOXL: Why These Stocks Plunged Double Digits In After-Hours Trading Today - Stocktwits

Sep 05, 2026

Passage Bio stock holds steady as investors weigh gene therapy pipeline and recent losses - AD HOC NEWS

Sep 05, 2026

Sep 03, 2026

Passage Bio Amends Remix Merger, Private Financing Terms - TipRanks

Sep 03, 2026

[425] Passage BIO, Inc. Business Combination Communication | PASG SEC FilingForm 425 - Stock Titan

Sep 03, 2026

Passage Bio Revises Remix Merger to Two-Step Structure, Adds $70 Million Pre-Funded PIPE - TradingView

Sep 03, 2026

Remix deal would leave Passage Bio (NASDAQ: PASG) investors a small slice of the combined company - Stock Titan

Sep 03, 2026

Fierce Biotech Layoff Tracker 2026: Novartis nixes Swiss site; TScan telegraphs 75% headcount drop - Fierce Biotech

Sep 03, 2026

Sep 02, 2026

Passage Bio stock reacts to reverse split as investors watch next steps - AD HOC NEWS

Sep 02, 2026

Aug 30, 2026

PASG Stock Slumps 16% After-Hours — What’s Driving The Selloff? - Stocktwits

Aug 30, 2026

Aug 20, 2026

Passage (PASG) Earnings Update: EPS Exceeds Its Estimate in the Latest Reading; Trading Move: Shares Fall 0.22% in the Current UpdateTech Earnings Analysis - vinanet.vn

Aug 20, 2026

Aug 19, 2026

GM1 Gangliosidosis Market Research Explores Growth Within A $0.95 Billion Opportunity - openPR.com

Aug 19, 2026

Layoff Tracker: Kolon TissueGene cuts 37 US staffers after Phase 3 fail - BioSpace

Aug 19, 2026

Aug 14, 2026

Vestal Point Capital (PASG) filing shows no current Passage Bio share ownership - Stock Titan

Aug 14, 2026

Passage Bio | SCHEDULE 13G/A: Others - Moomoo

Aug 14, 2026

Aug 12, 2026

PASG Q2 2026 Earnings: Narrower-than-Expected Loss Drives 2% Share GainSpecial Dividend Alert - Vinanet

Aug 12, 2026

Aug 10, 2026

Passage Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 10, 2026

Passage Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 10, 2026

Passage Bio Q2 Results: EPS beats estimates, losses narrow YoY - scanx.trade

Aug 10, 2026

Passage Bio Q2 net loss narrows 16.67% to $7.82 million - Bitget

Aug 10, 2026

Passage BIO, Inc. 2026: Revenue ($7.82M), Net income ($7.82M), EPS ($2.44) — 10-Q Summary - TradingView

Aug 10, 2026

PASG: Pending merger with Remix is vital as cash dwindles and operations wind down - TradingView

Aug 10, 2026

Passage Bio (PASG) outlines Q2 2026 loss, cash strain and Remix merger terms - Stock Titan

Aug 10, 2026

Aug 07, 2026

Passage Bio Inc expected to post a loss of $2.65 a shareEarnings Preview - TradingView

Aug 07, 2026